Preclinical Imaging Market Share

Global Preclinical Imaging Market Overview

Preclinical Imaging Market Size was valued at USD 4.62 Billion in 2023. The Global Preclinical Imaging industry is projected to grow from USD 4.97 Billion in 2024 to USD 8.33 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.90 % during the forecast period (2024 - 2032).

In September 2023, Revvity, Inc., a US-based company, unveiled three new systems as part of its improved imaging portfolio. These systems aim to promote innovation in preclinical research across many applications. The cited breakthroughs include the IVIS Spectrum 2 and IVIS SpectrumCT 2 imaging systems, which signify a development in the domain of in vivo optical imaging by enhancing both sensitivity and adaptability. Moreover, the Quantum GX3 microCT structural imaging solution has been introduced. This breakthrough improves the velocity and clarity of imaging done outside of the body (ex vivo) and inside the body (in vivo), therefore assisting scientists in studying the biology of diseases and assessing prospective treatments. Revvity's premium preclinical imaging portfolio encompasses a wide range of products, such as reagents, software tools for data analysis, 2D and 3D optical imaging, microCT imaging, ultrasound platforms, and reagents.

Mediso unveiled spinScan® in April 2023, a state-of-the-art MRI spectrometer that replaces the previous console of the nanoScan® MRI product range. The new spectrometer is specifically designed for MRI applications and has an extendable RF front-end. It also offers real-time dynamic shimming and exceptionally low noise. In order to offer a complete MRI workflow, the spectrometer is combined with three software applications created by Mediso: the Sequence Development Platform, which allows for complete control over the reconstruction algorithms and pulse sequences; and the InterView™ FUSION and Nucline™, which are software packages that have been clinically validated and approved by the FDA. These packages are used for routine acquisition planning, reconstruction, image post-processing, and evaluation. The spinScan® spectrometer is based on a technology that has been continuously developed for more than ten years. It consists of an FPGA SoC platform with a transceiver architecture that is highly scalable. This architecture allows for more than 128 receiver channels, microsecond gradient resolution, and closed-loop control through high-speed optical interfaces.

 Preclinical Imaging Market Trends

• Increased demand for certified Preclinical Imaging products to propel market growth

Pharmaceutical research and development (R&D) funding comes from both public and private sources. Governments primarily supported basic and early-stage research prior to COVID-19 through budgetary allocations, research grants, and public ownership of research and higher education institutions. Although it frequently receives support from R&D subsidies or tax credits, the pharmaceutical industry invests in research and development at all stages, contributing the most to knowledge translation and application for creating new products. According to the OECD, Governments in the 33 OECD nations budgeted a total of about USD 67 billion for R&D in the health sector in 2018. Moreover, according to the statistics Science and Engineering Indicators, Based on R&D expenditures, a small number of nations handle the majority of R&D. About half of the world's R&D was carried out in 2019 by the United States (27% or $656 billion) and China (22% or $526 billion). South Korea (4%), Germany (6%), and Japan (7% each) also contributed significantly. Other top performers, like France, India, and the United Kingdom, make up between 2% and 3% of the total. Thus, as the R&D spending increased, the demand for equipment used for imaging in these studies was also fuelled. This factor is driving the market CAGR.

Figure 1: Translational Research: Preclinical and Clinical TrialsSource: Secondary Research, Primary Research, MRFR Database, and Analyst Review

For many years, using animal models has been essential in developing safe therapeutics for patients. These models, however, have the challenging task of roughly simulating the human body, and they frequently fall short. 90% of drugs that fail in Phase 1 clinical trials do so because of toxicity, including inarigivir and many other drugs. To overcome this barrier, companies are continuously advancing their equipment such that they can perform more effective trials. Preclinical imaging is essential for drug discovery, phenotyping, and gaining a fundamental understanding of disease mechanisms. It is difficult to adapt imaging techniques from humans to small animals. Imaging methods are used more frequently in oncology clinical trials to provide information for making decisions. Key study endpoints are increasingly defined using traditional morphological imaging methods and standardized response criteria based on tumor size measurements. Primary, secondary, and exploratory study endpoints are largely produced by non-invasive imaging techniques like computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Thus, the growing use of preclinical imaging is one of the key factors boosting the Preclinical Imaging market revenue globally.

Preclinical Imaging Market Segment Insights

Preclinical Imaging Product Insights

The market segments of Preclinical Imaging, based on Product, includes optical imaging, nuclear imaging, micro-MRI, micro-ultrasound, micro-CT, and photoacoustic imaging systems. The optical imaging segment held the majority share in 2022 in the Preclinical Imaging market data. This is due to their widespread use in projects to discover new drugs and image small animals. During the forecast period the Micro-ultrasound segment is expected to grow at the fastest CAGR during the forecast period. Micro-ultrasound, a scaled-down variation of ultrasound, has a wider range of uses, particularly in studies involving small animal models. These more compact imaging methods increase the effectiveness of the methods. Further, the multi-modal imaging devices segment is expected to register a significant growth rate. New-generation devices with integrated imaging technologies are expected to accelerate the growth of the multi-modal imaging devices market in preclinical studies. Technology advancements have led to the development of integrated systems that include molecular and anatomical digital imaging systems and enable multiple screenings in a single unit.

Figure 2: Preclinical Imaging Market, by Product, 2023 & 2032 (USD Billion)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Preclinical Imaging Reagent Insights

The Preclinical Imaging market data, based on reagents, include optical, nuclear, CT contrast agents, and MRI contrast agents. The optical segment dominated the market revenue of Preclinical Imaging in 2022. The growing use of optical imaging is furling the demand for optical reagents, given that all imaging procedures use these products extensively. Therefore, buying these products is common. CT contrast agents are projected to be the faster-growing segment during the forecast period.

Preclinical Imaging Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Preclinical Imaging market accounted for USD 36.4 billion in 2022, with a share of around 45.80%, and is expected to exhibit a significant CAGR growth during the study period. Higher adoption rates of technologically advanced devices in the area, developed infrastructure, and a large number of preclinical projects. The region's greater adoption of technologically advanced devices, the accessibility of skilled professionals, the volume of preclinical projects, and so forth. New clinical research and development projects are also being encouraged by government initiatives in this region.

Further, the major countries studied in the market report are: The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: PRECLINICAL IMAGING MARKET SHARE BY REGION 2023 (%)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Preclinical Imaging market accounts for the second-largest market share. In-vivo imaging systems are becoming more widely used in Preclinical research due to the growing number of clinical research organizations (CROs) and pharmaceutical companies, further accelerating the growth of this market. Moreover, the UK market of preclinical Imaging held the largest market share, and the Germany market of preclinical Imaging was the fastest-growing market in the region.

Asia Pacific Preclinical Imaging Market is expected to grow at the fastest CAGR from 2024 to 2032. The region is becoming more appealing for preclinical research studies due to low research costs, laxer regulatory requirements, and increased government funding for developing the research and development sector in the respective countries. Moreover, The factors attributing to the market development include expanded public-private initiatives, innovative advances in molecular imaging, and expanded market interest in non-intrusive small animal imaging methods. Further, the China market of preclinical Imaging held the largest market share, and the India market of preclinical Imaging was the fastest-growing region.

Preclinical Imaging Key Market Players & Competitive Insights

Major market players are investing & funding to support the R&D activities such that they can launch new medicines in the market. Companies are also taking initiatives to grow their market share, with key market developments such as new product launches, increased investments, growing product pipelines, and collaboration with other companies. The government constantly supports players in the Preclinical Imaging industry to launch new products.

Several start-up companies are also entering the Preclinical Imaging industry by raising funds to develop their products. The Preclinical Imaging markets major player such as Bruker Corporation (US), MR Solutions (UK), PerkinElmer (US), Fujifilm Holdings Corporation (Japan), Milabs B.V. (The Netherlands), Mediso Ltd. (Hungary), Miltenyi Biotec GmbH (Germany), LI-COR Inc. (US), Aspect Imaging (Israel), and Trifoil Imaging (US) are launching new products in the market.

Bruker Corporation (US) is a life science research and diagnostics solutions company dedicated to researching and providing solutions for the healthcare sector. In May 2022, Tesla Bruker announced the launch of innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets. The new range of Maxwell 7 Tesla and 9.4 Tesla magnets is anticipated to follow its BioSpec Maxwell 3 Tesla model's success, eliminating the need for liquid Helium or Nitrogen refills while providing high-field sensitivity and resolution for cutting-edge preclinical MRI and PET/MR research.

PerkinElmer (US) is one of the top manufacturers of preclinical imaging systems, including the widely used IVIS optical imaging platform. These systems cover a variety of modalities, including ultrasound, optical, and micro CT. In April 2022, PerkinElmer introduced the Vega imaging system. This first-of-its-kind ultrasound platform combines hands-free, automated technology with the high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology, and more.

Key Companies in the market of preclinical Imaging includes

• 
  

  Bruker Corporation (US)

  
  


• 
  

  MR Solutions (UK)

  
  


• 
  

  PerkinElmer (US)

  
  


• 
  

  Fujifilm Holdings Corporation (Japan)

  
  


• 
  

  Milabs B.V. (The Netherlands)

  
  


• 
  

  Mediso Ltd. (Hungary)

  
  


• 
  

  Miltenyi Biotec GmbH (Germany)

  
  


• 
  

  LI-COR Inc. (US)

  
  


• 
  

  Aspect Imaging (Israel)

  
  


• 
  

  Trifoil Imaging (US), among others

  
  

Preclinical Imaging Industry Developments

October 2021:MILabs is raising the value of its ecosystem of preclinical products to a completely new level under the new ownership of the Rigaku Group (Tokyo, Japan). The user experience has been elevated with MILabs' new series seven integrated line of products by highlighting how well each modality functions independently and how much better they are when they all function together.

October 2019:MR Solutions unveiled a full line of cutting-edge PET/CT preclinical imaging systems last week in Barcelona at EANM '19, the European Association of Nuclear Medicine. The four-model range, which includes a small benchtop PET/CT, can hold small animals weighing up to 12 kg.

Preclinical Imaging Market Segmentation

Preclinical Imaging Product Outlook  

• 
  

  Optical Imaging

  
  


• 
  

  Nuclear Imaging

  
  


• 
  

  Micro-MRI

  
  


• 
  

  Micro-Ultrasound

  
  


• 
  

  Micro-CT

  
  


• 
  

  Photoacoustic Imaging System

  
  

Preclinical Imaging Reagent Outlook 

• 
  

  Optical

  
  


• 
  

  Nuclear

  
  


• 
  

  CT Contrast Agents

  
  


• 
  

  MRI Contrast Agents

  
  

Preclinical Imaging Regional Outlook  

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America